产品名称 | NebuSelect™ Recombinant Cynomolgus NGAL/Lipocalin-2, His-tag |
---|---|
目录号 | NBL-241884 |
别名 | NGAL/Lipocalin-2 |
外观 | see COA |
分子量 | Gln21-Gly198 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | XP_005580845.3 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-241884-100ug | 100ug | Inquire | Inquire | |
NBL-241884-1mg | 1mg | Inquire | Inquire | |
NBL-241884-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Cynomolgus NGAL/Lipocalin-2, His-tag
Catalog#:
NBL-241884
Description:
NebuSelect™ Recombinant Cynomolgus NGAL/Lipocalin-2, His-tag(Cat#NBL-241884) is expressed in HEK293 with His tag at the C-Terminus.It contains Gln21-Gly198.
Species:
Cynomolgus
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 21.51 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Target Name:
NGAL/Lipocalin-2
Target Information:
Acute kidney injury (AKI) is one of the most common complications of various serious conditions, and early diagnosis is therefore critical for the treatment of AKI. Recent evidence demonstrates that neutrophil gelatinase- associated lipocalin (NGAL) is closely associated with AKI. Several experimental and clinical studies have shown that the expression of urine and serum NGAL increases significantly in AKI. NGAL shows potential to be a new effective early biochemical marker of AKI. Further studies are needed to confirm the significant advantages of NGAL in the diagnosis of early AKI and its value in clinical applications.
Amino Acid Sequence:
Gln21-Gly198
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.